HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Keros Therapeutics (NASDAQ:KROS) and maintained a $100 price target.
August 07, 2023 | 6:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Keros Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $100.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Keros Therapeutics. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100